Corvista Health’s point-of-care device, which can be used to predict pulmonary hypertension in a noninvasive way, also appears to work well at identifying heart failure, accurately detecting patients who have it while ruling it out in others, a study found. Using machine learning to decode data from patients,…
Celastrol, a herbal compound used in traditional Chinese medicine, may help prevent pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) by reducing inflammation and protecting lung tissue from damage, a study in rats and lab-grown cells suggests. While these preclinical findings are promising, the compound is still experimental and more…
Seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH) in the pipeline of Gossamer Bio, continues to reduce the resistance blood faces moving into the lungs when added to standard of care treatment for PAH, according to data from a long-term extension part of a Phase 2 clinical…
People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3…
An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by Chinese scientists found. According to the researchers, HIF-1alpha may worsen PAH by increasing the uptake…
Children with pulmonary hypertension (PH), characterized by high blood pressure in the lungs that can make exercising difficult, are more likely to be active if physical activity is fun, allows them to be with friends, and puts them in a safe place where they feel included, a study has…
Having fewer very fine blood vessels in the fold of skin at the base of the fingernails appears to be linked to an increased risk of clinical worsening in pulmonary arterial hypertension (PAH), a study in the Netherlands suggests. People with chronic thromboembolic pulmonary hypertension (CTEPH) also had…
Tyvaso (inhaled treprostinil) appears to be well tolerated by patients with different types of pulmonary hypertension (PH), and stopping the treatment increases the risk of disease worsening, a study found. The study, “Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil,”…
Liquidia is suing the U.S. Food and Drug Administration (FDA) to challenge a decision that delays the final approval of Yutrepia, its inhaled dry-powder formulation of treprostinil, arguing that the delay unfairly limits patient access to important treatment. Yutrepia was granted tentative approval in 2021 to improve the…
Airplane travel appears to be safe for people with pulmonary hypertension (PH) with both slight and marked limitations of physical activity, though some individuals may need oxygen support on board to help with breathing, according to a new study. While some patients in the study, dubbed PEGASUS (NCT03051763),…
The U.S. Food and Drug Administration (FDA) has extended its tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil, to pulmonary hypertension associated with interstitial lung disease (PH-ILD), a condition that causes the lungs to become scarred. Liquidia’s Yutrepia was granted tentative approval in 2021…
How chronic thromboembolic pulmonary hypertension (CTEPH) is managed across regions globally varies widely despite treatment advances, a survey study found, highlighting the need for more research, better guidelines, and ongoing education for healthcare providers. The study, “Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A…
Get regular updates to your inbox.